(Q43522124)

24 November 2017

Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience (English)

1 reference

24 November 2017

8

Razelle Kurzrock

1 reference

Apostolia Maria Tsimberidou

24 November 2017

2

object named as

Apostolia M Tsimberidou

1 reference

24 November 2017

4

Aung Naing

1 reference

24 November 2017

Jennifer Wheler

1

1 reference

24 November 2017

David Hong

3

1 reference

24 November 2017

Tiffiny Jackson

5

1 reference

24 November 2017

Suyu Liu

6

1 reference

24 November 2017

Lei Feng

7

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

24 November 2017

1 reference

24 November 2017

115

1 reference

24 November 2017

1091-1099

1 reference

24 November 2017

5

1 reference

Thrombosis in patients with cancer

24 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

Role of platelets in tumor cell metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Risks and benefits of phase 1 oncology trials, revisited

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Participants in phase 1 oncology research trials: are they vulnerable?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Pathophysiology of the thrombophilic state in the cancer patient

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Prognosis of Cancers Associated with Venous Thromboembolism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

THROMBOCYTOSIS ASSOCIATED WITH MALIGNANT DISEASE

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Prognostic markers in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Poor prognosis associated with thrombocytosis in patients with gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24018

7 January 2021

Identifiers

DOI

10.1002/CNCR.24018

1 reference

24 November 2017

1 reference